Champions Oncology (NASDAQ:CSBR) Stock Crosses Below 200 Day Moving Average – Here’s What Happened

Champions Oncology, Inc. (NASDAQ:CSBR)’s stock price crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $6.46 and traded as low as $5.90. Champions Oncology shares last traded at $6.1990, with a volume of 6,648 shares traded.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered Champions Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, April 27th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Champions Oncology Stock Performance

The company has a market cap of $86.09 million, a price-to-earnings ratio of -38.74 and a beta of 0.43. The business has a 50-day simple moving average of $5.95 and a 200-day simple moving average of $6.46.

Institutional Trading of Champions Oncology

A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in Champions Oncology by 1.9% during the 3rd quarter. Vanguard Group Inc. now owns 333,258 shares of the biotechnology company’s stock worth $2,158,000 after buying an additional 6,229 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in Champions Oncology by 28.7% during the 1st quarter. Acadian Asset Management LLC now owns 39,511 shares of the biotechnology company’s stock worth $341,000 after buying an additional 8,814 shares during the last quarter. XTX Topco Ltd purchased a new stake in Champions Oncology during the 2nd quarter worth about $103,000. Essex Investment Management Co. LLC purchased a new stake in Champions Oncology during the 4th quarter worth about $126,000. Finally, Jane Street Group LLC purchased a new stake in Champions Oncology during the 1st quarter worth about $200,000. 41.30% of the stock is owned by hedge funds and other institutional investors.

About Champions Oncology

Champions Oncology, Inc engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients.